Redeye concludes that Litium delivered a strong Q4, with ARR growth of 18% including Geins and organic growth of 9%.
Redeye comments on Litium’s Q4, which showed solid momentum with 18% ARR growth and net sales above our expectations.
Redeye comments on Litium’s announcement of a strategic partnership with Monitor ERP, where Litium becomes one of Monitor’s recommended e-co...
Redeye comments on Litium’s Q3 report, which included a solid organic ARR growth of 11%.
Redeye provides a preview of Litium’s Q3 results, set to be released on 23 October.
Redeye provides an update following Litium’s acquisition of Geins, a small but strategically sound deal that brings both technical capabilit...
This morning, Litium announced the acquisition of Geins, a SaaS e-commerce platform with strong AI and automation capabilities, and a fully ...
Redeye lifts its ARR and EBITDA-CAPEX estimates for Litium after the Q2 report, where ARR growth significantly exceeded expectations.
Redeye comments on Litium’s Q2 report, returning to a solid ARR growth of 12%.
Redeye initiates coverage of Litium, a Nordic mid-market-focused SaaS platform for digital commerce.
Minor estimate changes Record-level client intake & variable intake growth EV/ARR 2x, '25e EV/EBITDA ~8x Q1 slightly below expectations The...
Sales in line with ABGSCe, ARR slightly below Limited, downward consensus estimate revisions Highlights record-high client intake Q1'25 rep...
We trim '25e-'27e ARR by 1-3% on continued macro weakness Volume-based revenue growth could pick up in H2'25e EV/ARR ~2x, '25e EV/EBITDA ~8x...
Minor estimate changes Potential start of variable revenue acceleration EV/ARR 2x, '25e EV/EBITDA ~8x Q4 in line The Q4 report was in line ...
Sales slightly above ABGSCe, ARR in line Limited consensus estimate revisions are likely Variable revenue on the rise Q4'24 report Litium r...
We trim '25e-'26e ARR by 1% on continued macro weakness Still awaiting a return in B2C business momentum EV/ARR ~2x, '25e EV/EBITDA ~8x Wha...
- Minor estimate changes - Solid profitability ahead as growth conditions stall - EV/ARR 1.
Sales and ARR in line with ABGSCe Limited consensus estimate revisions are likely Strong margin due to solid cost control Q3'24 report Liti...
We trim '24e-'26e ARR by 1% on continued macro weakness Still awaiting a return in B2C business momentum EV/ARR ~2x, '24e EV/EBITDA ~9x Wha...
- Marginal estimate changes - Awaiting B2C and B2B volume recovery for growth upside - EV/ARR ~2.
- Sales and EBITDA in line with ABGSCe - Simplicity and predictability likely to drive limited cons.
- We cut '24e-'26e ARR by 2-3% on continued macro weakness - Still awaiting a return in B2C business momentum - EV/ARR ~2.
- '24e sales up 2% - New ARR shows sequential growth stability - '24e-'25e EV/EBITDA ~11-9x Another solid Q1 report The Q1 report beat our s...
Sales +10%, EBITDA +13% vs. ABGSCe New ARR definition more comparable with peers Cost base discipline drives margins Q1'24 report Litium re...
'24e-'26e ARR cut by 2-3% on continued macro weakness B2C business momentum likely to return in H2'24 EV/ARR ~2x, '24e EV/EBITDA ~11x What ...
Minor '24e-'25e EBITDA estimate changes We deem positive EBIT in '24 to be a credible target EV/ARR 2.
ARR +6% y-o-y, 3% below ABGSCe Surprisingly large beat on EBITDA (+99% vs.
'24e-'25e EBITDA cut by 9-6% on tough macro Growth somewhat more muted on lighter investments EV/ARR ~2x, '24e EV/EBITDA ~11x What to look ...
'23e-'25e sales cut by 0-3% On the right path toward cash flow generation EV/ARR 1.
ARR +9% y-o-y, in line with ABGSCe Outlook unchanged despite a tougher market Cons.
'23e-'25e sales cut by 1-5% B2C volume recovery likely to take longer than expected EV/ARR 1.
• Minor estimate revisions • ARR growth streak untouched • EV/ARR ~2x, '23e EV/EBITDA 19x Q2'23 report in brief The report was mostly in lin...
• ARR +8% y-o-y, in line with ABGSCe • Cons. likely to make marginally pos.
• Cost initiatives announced • One step closer to positive FCF • Trading at '23e EV/EBITDA of ~21x What to look for in Q2'23e For Q2, we exp...
We cut '23e-'25e ARR by 1% ARR growth streak untouched EV/ARR 2.
ARR +7% y-o-y, in line with ABGSCe Cons. likely to make minor neg.
Cut Q1'23e sales by 2% Resiliency due to high share of recurring revenue Long-term prospects intact
Pathway to positive FCF significantly clearer More resilient to B2C volumes than we expected EV/ARR 2.
ARR +10% y-o-y, +3% vs ABGSCe Cons. likely to make pos.
Cut Q4'22e sales by 15% Swedish consumer confidence at 25-year low Long-term prospects intact Q4'22 estimates Swedish consumer confidence h...
ARR of SEK 67.4m, up 15% y-o-y, -3% vs. ABGSCe Committed to cash flow break-even Share trading at ’23e 12.
ARR +15% y-o-y, -3% vs ABGSCe Expect minor est. revisions Webcast scheduled for 11:00 CET Q3 results ARR SEK 67.
Q3 report due Thursday, 27 October Growth muted but profitability still in sight B2B likely to offer downside protection for now Q3’22 ex...
We hosted a presentation with CEO Patrik Settlin today B2B and indexed contracts mitigate inflation woes Profitability still in sight A N...
ARR of SEK 67m, up 19% y-o-y, -2% vs. ABGSCe Breakthrough deal in the US with a B2B customer Share trading at 2.
New communication around financial target… …” balance between profitability and growth” The share trades at 2.
ARR +19% y-o-y. -0.7% vs. ABGSC Expect cons. to make relatively small forecast changes Webcast scheduled for 10:00 CET Q1 results Q1: ARR S...
Q2’21 ARR SEK 57m, up 21.5% y-o-y Growth could ramp up in ’22e, driven by Litium 8 Fair value range adjusted to SEK 19-45 (19-43) per share ...
